PUBLIC HEALTH ASSESSMENT
PANTEX PLANT
AMARILLO, CARSON COUNTY, TEXAS
| Table 1 Summary of Birth Defect Check Box Categories in theTexas Birth Certificate and Fetal Death Certificate (11) | |
|---|---|
| Category of BirthDefect | Description of Birth Defect Category |
| Anencephalus | Congenital absence of the cranial vault, with cerebralhemispheres completely missing or reduced to small massesattached to the base of the skull. |
| Spina Bifida /meningocele | A developmental anomaly characterized by defective closure ofthe bony encasement of the spinal cord, through which the cordand meninges may or may not protrude. |
| Hydrocephalus | A condition characterized by abnormal accumulation of fluid inthe cranial vault, accompanied by enlargement of the head. |
| Microcephalus | Abnormal smallness of the head. |
| Other central nervoussystem anomalies | |
| Heart malformations | Malformations of the heart. |
| Other circulatory /respiratory anomalies | |
| Rectal atresia / stenosis | Atresia (imperforation; absence or closure of normal opening) orstenosis (narrowing) of the rectum or anus. |
| Tracheo-esophagealfistula / esophagealatresia | Tracheo-esophageal fistula: opening between the trachea andesophagus. Atresia: absence of open canal of the esophagus. |
| Omphalocele /gastroschisis | Protrusion at birth of part of the intestine through a large defectin the abdominal wall. In omphalocele, usually covered by athin membrane. Different etiologies. |
| Other gastrointestinalanomalies | |
| Malformed genitalia | |
| Renal agenesis | Congenital absence of one or both kidneys. |
| Other urogenitalanomalies | |
| Cleft lip/palate | Fissure or gap in the upper lip and/or palate. |
| Polydactyly / syndactyly | Polydactyly: too many fingers or toes. Syndactyly: fingers or toes fused together. |
| Limb reductions | Parts of hand, arm, foot, or legs missing. |
| Club foot | A deformity of the foot in which it is twisted out of shape orposition, referred to medically as talipes. |
| Diaphragmatic hernia | The protrusion of an organ through a defect in the diaphragm. |
| Other musculoskeletal /integumental anomalies | |
| Down syndrome | A chromosomal abnormality characterized by moderate tosevere mental retardation, epicanthal folds in eyes, slopingforehead, flat-bridged nose, short phalanges. Caused by an extrachromosome 21 (trisomy 21). Old name: mongolism (due tocharacteristic eye features). |
| Other chromosomalanomalies | Several, including trisomy 13 (Patau syndrome), trisomy 18(Edward syndrome). |
| Other congenitalanomalies | Catchall category, if something present that doesn't fit into oneof the categories above. |
References: California Birth Defects Monitoring Program. A glossary of birth defects terminology. 1983.
Goodman RM, Gorlin RJ. The Malformed Infant and Child: An Illustrated Guide (Glossary). New York; Oxford University Press, 1983.
The following table was not available in electronic format for conversion to HTML at the time of preparation of this document. To obtain a hard copy of the document, please contact:
Agency for Toxic Substances and Disease Registry
Division of Health Assessment and Consultation
Attn: Chief, Program Evaluation, Records, and Information Services Branch E-56
1600 Clifton Road NE, Atlanta, Georgia 30333
The following table was not available in electronic format for conversion to HTML at the time of preparation of this document. To obtain a hard copy of the document, please contact:
Agency for Toxic Substances and Disease Registry
Division of Health Assessment and Consultation
Attn: Chief, Program Evaluation, Records, and Information Services Branch E-56
1600 Clifton Road NE, Atlanta, Georgia 30333
Appendix E
The following table was not available in electronic format for conversion to HTML at the time of preparation of this document. To obtain a hard copy of the document, please contact:
Agency for Toxic Substances and Disease Registry
Division of Health Assessment and Consultation
Attn: Chief, Program Evaluation, Records, and Information Services Branch E-56
1600 Clifton Road NE, Atlanta, Georgia 30333
The following table was not available in electronic format for conversion to HTML at the time of preparation of this document. To obtain a hard copy of the document, please contact:
Agency for Toxic Substances and Disease Registry
Division of Health Assessment and Consultation
Attn: Chief, Program Evaluation, Records, and Information Services Branch E-56
1600 Clifton Road NE, Atlanta, Georgia 30333
The following table was not available in electronic format for conversion to HTML at the time of preparation of this document. To obtain a hard copy of the document, please contact:
Agency for Toxic Substances and Disease Registry
Division of Health Assessment and Consultation
Attn: Chief, Program Evaluation, Records, and Information Services Branch E-56
1600 Clifton Road NE, Atlanta, Georgia 30333
Appendix E
1 Significantly higher (at the 5% level) than expected.
| MALES | ||||
|---|---|---|---|---|
| Site | Observed | Expected | SIR | 95% CI |
| Lung | 7 | 12.47 | 0.56 | 0.23-1.16 |
| Bone | 0 | 0.09 | - | - |
| Prostate | 8 | 22.30 | 0.36* | 0.15- 0.71 |
| Brain | 1 | 0.96 | 1.04 | 0.03-5.80 |
| Thyroid | 0 | 0.31 | - | - |
| Leukemia | 2 | 1.90 | 1.05 | 0.13-3.80 |
| All Sites | 52 | 72.17 | 0.72* | 0.54- 0.94 |
| FEMALES | ||||
| Site | Observed | Expected | SIR | 95% CI |
| Lung | 2 | 8.66 | 0.23* | 0.03- 0.83 |
| Bone | 0 | 0.11 | - | - |
| Breast | 6 | 18.47 | 0.32* | 0.12- 0.71 |
| Brain | 0 | 0.79 | - | - |
| Thyroid | 0 | 0.72 | - | - |
| Leukemia | 1 | 1.37 | 0.73 | 0.02-4.07 |
| All Sites | 26 | 61.44 | 0.42* | 0.28- 0.62 |
Note: The SIR (standardized incidence ratio) is defined as the number of observed cases divided by the number of expected cases. The latter is based on race-, sex-, and age-specific cancer incidence rates for California, 1988-1992 (cancer incidence rates for five regions of Texas, 1985-1991 were used to calculate bone cancer expected cases because California rates were not available).
* Significantly lower (at the 5% level) than expected.
Appendix E
| MALES | ||||
|---|---|---|---|---|
| Site | Observed | Expected | SIR | 95% CI |
| Lung | 28 | 30.86 | 0.91 | 0.60-1.31 |
| Bone | 0 | 0.28 | - | - |
| Prostate | 46 | 52.40 | 0.88 | 0.64-1.17 |
| Brain | 0 | 2.71 | - | - |
| Thyroid | 0 | 0.93 | - | - |
| Leukemia | 5 | 4.83 | 1.04 | 0.34-2.42 |
| All Sites | 150 | 178.88 | 0.84* | 0.71- 0.98 |
| FEMALES | ||||
| Site | Observed | Expected | SIR | 95% CI |
| Lung | 10 | 21.65 | 0.46* | 0.22- 0.85 |
| Bone | 1 | 0.32 | 3.13 | 0.08-17.41 |
| Breast | 35 | 48.58 | 0.72 | 0.50-1.00 |
| Brain | 3 | 2.18 | 1.38 | 0.28-4.02 |
| Thyroid | 1 | 0.08 | 12.50 | 0.32-69.64 |
| Leukemia | 6 | 3.40 | 1.76 | 0.65-3.84 |
| All Sites | 136 | 156.14 | 0.87 | 0.73-1.03 |
Note: The SIR (standardized incidence ratio) is defined as the number of observed cases divided by the number of expected cases. The latter is based on race-, sex-, and age-specific cancer incidence rates for California, 1988-1992 (cancer incidence rates for five regions of Texas, 1985-1991 were used to calculate bone cancer expected cases because California rates were not available).
* Significantly lower (at the 5% level) than expected.
Appendix E
| MALES | ||||
|---|---|---|---|---|
| Site | Observed | Expected | SIR | 95% CI |
| Lung | 624 | 626.49 | 0.99 | 0.92-1.08 |
| Bone | 7 | 7.18 | 0.97 | 0.39-2.01 |
| Prostate | 879 | 1011.32 | 0.87* | 0.81- 0.93 |
| Brain | 53 | 62.04 | 0.85 | 0.64-1.12 |
| Thyroid | 20 | 22.04 | 0.91 | 0.55-1.40 |
| Leukemia | 103 | 103.00 | 1.00 | 0.82-1.21 |
| All Sites | 3460 | 3662.52 | 0.94* | 0.91- 0.97 |
| FEMALES | ||||
| Site | Observed | Expected | SIR | 95% CI |
| Lung | 372 | 493.84 | 0.75* | 0.68- 0.83 |
| Bone | 4 | 8.48 | 0.47 | 0.13-1.21 |
| Breast | 906 | 1148.00 | 0.79* | 0.74- 0.84 |
| Brain | 42 | 53.77 | 0.78 | 0.56-1.06 |
| Thyroid | 67 | 62.33 | 1.07 | 0.83-1.37 |
| Leukemia | 88 | 82.37 | 1.07 | 0.86-1.32 |
| All Sites | 4015 | 3693.56 | 1.09** | 1.06-1.12 |
Note: The SIR (standardized incidence ratio) is defined as the number of observed cases divided by the number of expected cases. The latter is based on race-, sex-, and age-specific cancer incidence rates for California, 1988-1992 (cancer incidence rates for five regions of Texas, 1985-1991 were used to calculate bone cancer expected cases because California rates were not available).
* Significantly lower (at the 5% level) than expected.
** Significantly higher (at the 5% level) than expected.
Appendix E
| MALES | ||||
|---|---|---|---|---|
| County/Site# | Observed | Expected | SIR* | 95% CI |
| ARMSTRONG ALL AML CLL CML | 0 0 2 0 | 0.2 0.5 0.6 0.3 | - - 3.1 - | - - 0.4 -11.3 - |
| CARSON ALL AML CLL CML | 1 0 2 0 | 0.5 1.2 1.5 0.7 | 1.9 - 1.3 - | 0.0 -10.5 - 0.2 - 4.7 - |
| POTTER/RANDALL ALL AML CLL CML | 12 19 46 13 | 15.0 25.9 30.1 13.9 | 0.8 0.7 1.5** 0.9 | 0.4 - 1.4 0.4 - 1.2 1.1 - 2.0 0.5 - 1.6 |
Note: The SIR (standardized incidence ratio) is defined as the number of observed cases divided by the number of expected cases. The latter is based on race-, sex-, and age-specific cancer incidence rates for California during the period 1988-1993.
* The SIR has been rounded to the first decimal place.
** Significantly higher (at the 5% level) than expected.
# Acute lymphocytic leukemia (ALL), acute myelocytic leukemia (AML), chronic lymphocytic leukemia (CLL), and chronic myelocytic leukemia (CML)
| FEMALES | ||||
|---|---|---|---|---|
| County/Site# | Observed | Expected | SIR* | 95% CI |
| ARMSTRONG ALL AML CLL CML | 0 | 0.1 0.4 0.5 0.2 | - - 2.2 - | - - 0.1 -12.1 - |
| CARSON ALL AML CLL CML | 0 2 2 0 | 0.4 1.0 1.1 0.4 | - 2.1 1.9 - | - 0.3 - 7.5 0.2 - 6.8 - |
| POTTER/RANDALL ALL AML CLL CML | 10 24 33 11 | 11.8 23.8 23.9 9.6 | 0.8 1.0 1.4 1.1 | 0.4 - 1.6 0.7 - 1.5 1.0 -1.9 0.6 - 2.1 |
Note: The SIR (standardized incidence ratio) is defined as the number of observed cases divided by the number of expected cases. The latter is based on race-, sex-, and age-specific cancer incidence rates for California during the period 1988-1993.
* The SIR has been rounded to the first decimal place.
# Acute lymphocytic leukemia (ALL), acute myelocytic leukemia (AML), chronic lymphocytic leukemia (CLL), and chronic myelocytic leukemia (CML)
Appendix E
| MALES | ||||
| Site | Observed | Expected | SMR | 95% CI |
| Lung | 10 | 13.29 | 0.75 | 0.36-1.38 |
| Bone | 1 | 0.10 | 10.00 | 0.25-55.71 |
| Prostate | 3 | 4.55 | 0.66 | 0.14-1.93 |
| Brain | 1 | 0.83 | 1.20 | 0.03-6.71 |
| Thyroid | 0 | 0.04 | - | - |
| Leukemia | 2 | 1.51 | 1.32 | 0.16-4.78 |
| All Sites | 32 | 37.47 | 0.85 | 0.58-1.21 |
| FEMALES | ||||
| Site | Observed | Expected | SMR | 95% CI |
| Lung | 3 | 6.63 | 0.45 | 0.09-1.32 |
| Bone | 0 | 0.08 | - | - |
| Breast | 5 | 4.51 | 1.11 | 0.36-2.59 |
| Brain | 0 | 0.68 | - | - |
| Thyroid | 0 | 0.07 | - | - |
| Leukemia | 1 | 1.11 | 0.90 | 0.02-5.02 |
| All Sites | 19 | 28.43 | 0.67 | 0.40-1.04 |
Note: The SMR (standardized mortality ratio) is defined as the number of observed deaths divided by the number ofexpected deaths. The latter is based on race-, sex-, and age-specific cancer mortality rates for Texas during theperiod 1985-1994.
Appendix E
| MALES | ||||
|---|---|---|---|---|
| Site | Observed | Expected | SMR | 95% CI |
| Lung | 24 | 32.60 | 0.74 | 0.47-1.10 |
| Bone | 0 | 0.28 | - | - |
| Prostate | 6 | 10.08 | 0.60 | 0.22-1.30 |
| Brain | 2 | 2.21 | 0.91 | 0.11-3.27 |
| Thyroid | 0 | 0.10 | - | - |
| Leukemia | 6 | 3.70 | 1.62 | 0.60-3.53 |
| All Sites | 68 | 90.73 | 0.75* | 0.58- 0.95 |
| FEMALES | ||||
| Site | Observed | Expected | SMR | 95% CI |
| Lung | 8 | 16.34 | 0.49* | 0.21- 0.96 |
| Bone | 0 | 0.20 | - | - |
| Breast | 6 | 11.48 | 0.52 | 0.19-1.14 |
| Brain | 4 | 1.78 | 2.25 | 0.61-5.75 |
| Thyroid | 0 | 0.16 | - | - |
| Leukemia | 6 | 2.63 | 2.28 | 0.84-4.97 |
| All Sites | 55 | 68.82 | 0.80 | 0.60-1.04 |
Note: The SMR (standardized mortality ratio) is defined as the number of observed deaths divided by the number of expected deaths. The latter is based on race-, sex-, and age-specific cancer mortality rates for Texas during the period 1985-1994.
* Significantly lower (at the 5% level) than expected.
Appendix E
| MALES | ||||
|---|---|---|---|---|
| Site | Observed | Expected | SMR | 95% CI |
| Lung | 384 | 368.52 | 1.04 | 0.94-1.15 |
| Bone | 1 | 3.34 | 0.30 | 0.01-1.67 |
| Prostate | 158 | 117.52 | 1.34* | 1.14-1.57 |
| Brain | 29 | 25.05 | 1.15 | 0.78-1.66 |
| Thyroid | 1 | 1.24 | 0.81 | 0.02-4.49 |
| Leukemia | 43 | 42.49 | 1.01 | 0.73-1.36 |
| All Sites | 1140 | 1044.87 | 1.09* | 1.03-1.16 |
| FEMALES | ||||
| Site | Observed | Expected | SMR | 95% CI |
| Lung | 211 | 211.36 | 1.00 | 0.87-1.14 |
| Bone | 4 | 2.89 | 1.38 | 0.38-3.54 |
| Breast | 175 | 156.19 | 1.12 | 0.96-1.30 |
| Brain | 31 | 23.27 | 1.33 | 0.91-1.89 |
| Thyroid | 2 | 2.39 | 0.84 | 0.10-3.02 |
| Leukemia | 39 | 37.23 | 1.05 | 0.74-1.43 |
| All Sites | 986 | 946.07 | 1.04 | 0.98-1.11 |
Note: The SMR (standardized mortality ratio) is defined as the number of observed deaths divided by the number of expected deaths. The latter is based on race-, sex-, and age-specific cancer mortality rates for Texas during the period 1985-1994.
* Significantly higher (at the 5% level) than expected.
Appendix E
| MALES | ||||
|---|---|---|---|---|
| Site | Observed | Expected | SMR | 95% CI |
| Lung | 202 | 292.98 | 0.69* | 0.60- 0.79 |
| Bone | 1 | 2.76 | 0.36 | 0.01-2.02 |
| Prostate | 101 | 75.85 | 1.33** | 1.08-1.62 |
| Brain | 25 | 23.00 | 1.09 | 0.70-1.60 |
| Thyroid | 0 | 0.97 | - | - |
| Leukemia | 17 | 33.34 | 0.51* | 0.30-0.82 |
| All Sites | 693 | 802.85 | 0.86* | 0.80- 0.93 |
| FEMALES | ||||
| Site | Observed | Expected | SMR | 95% CI |
| Lung | 129 | 161.01 | 0.80* | 0.67- 0.95 |
| Bone | 1 | 2.18 | 0.46 | 0.01-2.56 |
| Breast | 108 | 119.44 | 0.90 | 0.74-1.09 |
| Brain | 22 | 19.10 | 1.15 | 0.72-1.74 |
| Thyroid | 1 | 1.51 | 0.66 | 0.02-3.69 |
| Leukemia | 20 | 25.92 | 0.77 | 0.47-1.19 |
| All Sites | 601 | 676.20 | 0.89* | 0.82- 0.96 |
Note: The SMR (standardized mortality ratio) is defined as the number of observed deaths divided by the number of expected deaths. The latter is based on race-, sex-, and age-specific cancer mortality rates for Texas during the period 1985-1994.
* Significantly lower (at the 5% level) than expected.
** Significantly higher (at the 5% level) than expected.
Appendix E
| Disease | Observed | Expected | SMR | 95% CI |
|---|---|---|---|---|
| Muscular Dystrophy | 0 | 0.050 | -- | -- |
| Multiple Sclerosis | 0 | 0.105 | -- | -- |
| Amyotrophic LateralSclerosis | 0 | 0.293 | -- | -- |
| Lupus | 0 | 0.302 | -- | -- |
| Disease | Observed | Expected | SMR | 95% CI |
|---|---|---|---|---|
| Muscular Dystrophy | 0 | 0.142 | -- | -- |
| Multiple Sclerosis | 0 | 0.309 | -- | -- |
| Amyotrophic LateralSclerosis | 0 | 0.758 | -- | -- |
| Lupus | 2 | 0.830 | 2.41 | 0.29 - 8.70 |
* Significantly higher (at the 5% level) than expected.
Appendix E
| Disease | Observed | Expected | SMR | 95% CI |
|---|---|---|---|---|
| Muscular Dystrophy | 0 | 1.83 | -- | -- |
| Multiple Sclerosis | 5 | 3.97 | 1.26 | 0.41 - 2.93 |
| Amyotrophic LateralSclerosis | 12 | 9.55 | 1.26 | 0.65 - 2.20 |
| Lupus | 16 | 13.91 | 1.15 | 0.66 - 1.86 |
* Significantly higher (at the 5% level) than expected.
| Disease | Observed | Expected | SMR | 95% CI |
|---|---|---|---|---|
| Muscular Dystrophy | 0 | 1.50 | -- | -- |
| Multiple Sclerosis | 10 | 3.45 | 2.90* | 1.39 - 5.33 |
| Amyotrophic LateralSclerosis | 8 | 6.85 | 1.17 | 0.50 - 2.30 |
| Lupus | 5 | 8.63 | 0.58 | 0.19 - 1.35 |
* Significantly higher (at the 5% level) than expected.
Appendix E
| Disease | Observed | Expected | SMR | 95% CI |
|---|---|---|---|---|
| Muscular Dystrophy | 0 | 3.33 | -- | -- |
| Multiple Sclerosis | 15 | 7.42 | 2.02* | 1.13 - 3.34 |
| Amyotrophic LateralSclerosis | 20 | 16.41 | 1.22 | 0.74 - 1.88 |
| Lupus | 21 | 22.54 | 0.93 | 0.58 - 1.43 |
* Significantly higher (at the 5% level) than expected.


